Drug intelligence / Profile preview

TG4010 + cisplatin + vinorelbine

Development stage: Discontinued
Lead developer: Transgene
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intravenous

Overview

TG4010 + cisplatin + vinorelbine is a combination therapy for non-small cell lung cancer (NSCLC). TG4010 is a therapeutic cancer vaccine based on a modified vaccinia Ankara (MVA) virus that expresses the MUC1 tumor-associated antigen and interleukin-2 (IL-2). This combination has been studied in clinical trials for advanced NSCLC, where TG4010 is administered subcutaneously at a dose of 10^8 pfu weekly for six weeks and then every three weeks, alongside standard chemotherapy consisting of cisplatin and vinorelbine.

Targets

TUBB (Tubulin (alpha and beta subunits))MUC1 (Mucin-1 Antigen)DNA

Beyond the preview

Go deeper on TG4010 + cisplatin + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG4010 + cisplatin + vinorelbine.

Explore the full profile